Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion.

The partnership aims to enhance the discovery of RNA interference (RNAi) therapeutics by integrating Alnylam’s RNAi platform with Inceptive’s AI expertise, potentially accelerating timelines for innovative drug designs.

Alnylam aims to accelerate the discovery of novel RNAi therapeutics as it advances ambitious pipeline expansion goals as part of its Alnylam 2030 strategy.

Alnylam and Inceptive Nucleics Collaboration

The collaboration is valued at up to $2 billion, with an upfront consideration of $30 million, including cash and equity.

By combining their strengths, Alnylam and Inceptive aim to unlock new therapeutic designs and improve the productivity of experimental processes.

ALNY Technical Analysis: Trend, RSI And Key Support

Currently, Alnylam’s stock price is $296.00, which places it about 0.5% above its 20-day simple moving average (SMA) of $294.61.

The stock is trading 3.8% below its 50-day SMA of $307.82, indicating a bearish trend as the 20-day SMA is below the 50-day SMA, suggesting potential resistance at higher levels.

The Relative Strength Index (RSI) is at 46.01, indicating neutral momentum, suggesting that the stock is neither overbought nor oversold at this time.

This neutral reading implies that there may be room for movement in either direction, depending on upcoming catalysts or market conditions.

• Key Resistance: $317.50 — a nearby level where rebounds can stall, closely tied to recent pivot zones.
• Key Support: $284.50 — a level where buyers previously stepped in, aligning with the 52-week low zone.

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $438.47. Recent analyst moves include:

• Citigroup: Initiated with Buy (Target $380.00) (May 19)
• HC Wainwright & Co.: Buy (Maintains Target to $510.00) (May 5)
• RBC Capital: Outperform (Lowers Target to $445.00) (May 1)

How Alnylam (ALNY) Ranks On Value And Momentum

Below is the Benzinga Edge scorecard for Alnylam Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

• Value: 6.83 — The stock is trading at a premium relative to peers.
• Momentum: 10.33 — Indicates strong upward price movement in recent sessions.

The Verdict: Alnylam Pharmaceuticals’s Benzinga Edge signal reveals a growth-heavy profile, with strong momentum but a premium valuation. This suggests that while the stock is performing well, it may be priced for continued success in the market.

ALNY Top ETF Holdings And Passive Flow Exposure

• Tema Neuroscience and Mental Health ETF (NASDAQ:MNTL): 6.46% Weight
• iShares Biotechnology ETF (NASDAQ:IBB): 3.99% Weight
• Nuveen ESG Mid-Cap Growth ETF (BATS:NUMG): 3.72% Weight

ALNY Stock Price Activity: Alnylam Pharmaceuticals shares were up 1.79% at $297.81 at the time of publication on Thursday, according to Benzinga Pro data.

Photo via Shutterstock